ZyVersa Therapeutics, Inc.

ZVSA: 8-K · delisting

ZyVersa Therapeutics, Inc. announced that effective July 16, 2026, it ceased trading on the OTCQB Venture Market. Simultaneously, the company commenced trading on the OTC Pink Limited Market, representing a downgrade in its market tier and listing status.

SEC 8-K•3mo ago

ZVSA: 8-K · other

Independent director Min Chul Park resigned from the ZyVersa Therapeutics Board and its Compensation and Nominating Committees effective July 8, 2026, citing personal reasons rather than any disagreement with the company. To address limited cash resources, the Board and management are implementing cost-cutting measures, including voluntary reductions in compensation for Chief Executive Officer Stephen Glover and Chief Financial Officer Peter Wolfe. The company is also exploring strategic alternatives such as divesting product candidates VAR 200 and IC 100, reducing headcount, or potentially 'going dark' by suspending its obligations to file current and periodic reports with the SEC.

SEC 8-K•3mo ago

ZVSA: 10-Q · periodic report

ZyVersa Therapeutics, Inc. reported a net loss of $1.8 million for the three months ended March 31, 2026, compared to a net loss of $2.3 million for the same period in 2025. The decrease in net loss is primarily due to lower research and development and general and administrative expenses. The company's cash position as of March 31, 2026, was $302,660, a significant increase from $101,778 at the end of 2025. This increase is primarily due to the proceeds from a $1.0 million convertible note and warrants issued in February 2026. ZyVersa has a working capital deficit of $14.1 million as of March 31, 2026, which raises substantial doubt about its ability to continue as a going concern. The company has an accumulated deficit of $139.4 million and expects to continue incurring significant expenses and operating losses in the future.

SEC 10-Q•5mo ago